Selective and potent inhibitor of histone deacetylase (Ki = 3.4 nM). Active in vivo. Potential anti-cancer agent. Induces accelerated dedifferentiation of primordial germ cells (PGCs) into embryonic germ (EG) cells. Activates autophagy.
|Storage||Desiccate at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 302.37. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||3.31 mL||16.54 mL||33.07 mL|
|5 mM||0.66 mL||3.31 mL||6.61 mL|
|10 mM||0.33 mL||1.65 mL||3.31 mL|
|50 mM||0.07 mL||0.33 mL||0.66 mL|
The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.
References are publications that support the products' biological activity.
Durcova-Hills et al (2008) Reprogramming primordial germ cells into pluripotent stem cells. PloS ONE 3 e3531 PMID: 18953407
Yoshida et al (1990) Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J.Biol.Chem. 265 17174 PMID: 2211619
Vigushin et al (2001) Trichostatin A is a histone deacetylase inhibitor with potent antitumor activity against breast cancer in vivo. Clin.Cancer Res. 7 971 PMID: 11309348
Wharton et al (2000) Inhibition of mitogenesis in Balb/c-3T3 cells by trichostatin A. J.Biol.Chem. 275 33981 PMID: 10945992
Galluzzi et al (2017) Pharmacological modulation of autophagy: therapeutic potential and persisting obstacles. Nat.Rev.Drug.Discov. PMID: 28529316
If you know of a relevant reference for Trichostatin A, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: Trichostatin A, supplier, Histone, deacetylase, inhibitors, inhibits, HDAC, Deacetylases, TrichostatinA, stem, cells, epigenetics, Histone, Deacetylases, Tocris Bioscience
4 Citations for Trichostatin A
Citations are publications that use Tocris products. Selected citations for Trichostatin A include:
Xia et al (2013) Identification of repurposed small molecule drugs for chordoma therapy. Cancer Biol Ther 14 638 PMID: 23792643
Biernacka et al (2013) Hyperglycaemia-induced chemoresistance of prostate cancer cells due to IGFBP2. World J Gastroenterol 20 741 PMID: 23959956
Kobori et al (2010) Butyrate stimulates IL-32α expression in human intestinal epithelial cell lines. Oncogene 16 2355 PMID: 20480520
Franklin et al (2014) Increased long-term potentiation at medial-perforant path-dentate granule cell synapses induced by selective inhibition of histone deacetylase 3 requires Fragile X mental retardation protein. Neurobiol Learn Mem 114 193 PMID: 24956240
Do you know of a great paper that uses Trichostatin A from Tocris? If so please let us know.
Literature in this Area
Epigenetics Scientific Review
Written by Susanne Müller-Knapp and Peter J. Brown, this review gives an overview of the development of chemical probes for epigenetic targets, as well as the impact of these tool compounds being made available to the scientific community. In addition, their biological effects are also discussed. Epigenetic compounds available from Tocris are listed.
Epigenetics Research Bulletin
Produced by Tocris and updated in 2014, the epigenetics research bulletin gives an introduction into mechanisms of epigenetic regulation, and highlights key Tocris products for epigenetics targets including:
- DNA Methyltransferases
- Histone Deacetylases
- Histone Demethylases
- Histone Methyltransferases
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.